Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Anthem Inc. CORP UNIT 050118
ANTX | US
4.34
USD0.06
1.40%
ANTX | US
Loading StockChartView...
About Anthem Inc. CORP UNIT 050118
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
4.34
Open
4.30
High
4.44
Low
4.01
AN2 Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing treatments for rare chronic and serious infectious diseases. It is developing epetraborole which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park California.
View LessANTX | US
Risk
84.0
Sharpe
1.83
Luna's Score
58/100
Recommendation
Hold
Luna says (ANTX | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
88.7%1 month
84.0%3 months
235.4%6 months
176.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.32
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-2.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
129.52M
MarketCap(USD)
129.52M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-69.48
Short ratio
0.75
Short perc.
0.98
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.57
Range1M
1.57
Range3M
5.91
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.68
Price X volume
1.03M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.11 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.32 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 235.42 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 129.52M | 3.66B | Emerging |
